
ResMed (NYSE:RMD) shareholders elected all 10 director nominees and approved the company’s auditor and executive compensation proposals at its 2026 annual meeting, according to preliminary voting results announced at the virtual event.
Chairman and CEO Mick Farrell also used the meeting to review product development, an acquisition involving a treatment for restless legs syndrome and recent financial performance. He said his update would not include material public information beyond what the company had already discussed on its earnings call.
Shareholders approve three proposals
General Counsel and Secretary Mike Rider said 112,860,360 shares were represented at the meeting, or approximately 80.24% of shares outstanding and entitled to vote.
Preliminary results showed that shareholders elected Carol Burt, Jan De Witte, Christopher DelOrefice, Karen Drexler, Michael Farrell, Peter Farrell, Harjit Gill, John Hernandez, Nicole Mowad-Nassar and Desney Tan to serve until the 2027 annual meeting.
Shareholders also ratified PricewaterhouseCoopers as ResMed’s independent registered public accounting firm for the fiscal year ending June 30, 2027, and approved executive compensation on an advisory basis. Rider said final results and voting details would be filed with the U.S. Securities and Exchange Commission and the Australian Securities Exchange and made available on ResMed’s website.
Product and acquisition update
Farrell said ResMed had upgraded its myAir platform with an Equipment Care feature that shows patients when they need to replace items such as masks, tubing and filters. He said the company’s fabric masks were showing 6% higher adherence than their silicone equivalents and expressed hope that the recently released AirTouch F40 would achieve similar adherence levels.
Farrell also pointed to a demand-generation opportunity from pharmaceutical companies’ GLP-1 products. He said patients associated with those products were 11% more likely to start therapy, 3% more likely to resupply at one year and more than 7% more likely to resupply at three years.
Discussing inorganic growth, Farrell said ResMed had acquired a company with a product called Nidra, a noninvasive, drug-free treatment for restless legs syndrome. He described it as part of a new platform in noninvasive nerve stimulation for sleep health, breathing health and health technology at home.
Financial performance and outlook
Farrell said ResMed’s core business grew 7% in constant currency in the first quarter, while non-GAAP earnings per share rose 14%. The company returned more than $1 billion in capital, including $936 million from share repurchases and an accelerated share repurchase program, as well as dividends, he said.
Farrell said ResMed’s products had changed more than 162 million lives over the previous 12 months. He reiterated an aspiration to reach 500 million lives in 2030 and said the company planned double-digit annual growth in that measure through that year.
Rider said no shareholder questions had been submitted after Farrell’s remarks.
About ResMed (NYSE:RMD)
ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.
